S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
TSE:ATE

Antibe Therapeutics (ATE) Stock Forecast, Price & News

C$0.62
+0.01 (+1.64%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
C$0.61
▼
C$0.62
50-Day Range
C$0.56
▼
C$0.74
52-Week Range
C$0.56
▼
C$1.56
Volume
24,553 shs
Average Volume
33,553 shs
Market Capitalization
C$32.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$4.00

Antibe Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
545.2% Upside
C$4.00 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$16,900 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

See Top Rated MarketRank™ Stocks Here
Antibe Therapeutics logo

About Antibe Therapeutics (TSE:ATE) Stock

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Antibe Therapeutics Price Performance

Shares of TSE:ATE opened at C$0.62 on Friday. Antibe Therapeutics has a twelve month low of C$0.56 and a twelve month high of C$1.56. The firm has a market cap of C$32.30 million and a P/E ratio of -1.16. The company has a 50 day moving average of C$0.63 and a 200 day moving average of C$0.69. The company has a quick ratio of 11.92, a current ratio of 13.07 and a debt-to-equity ratio of 0.29.

Receive ATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATE Stock News Headlines

August 2, 2022 | theglobeandmail.com
Antibe Therapeutics Inc stock advanced on Friday.
July 14, 2022 | americanbankingnews.com
John Lawrence Wallace Sells 21,500 Shares of Antibe Therapeutics Inc. (TSE:ATE) Stock
July 14, 2022 | americanbankingnews.com
Antibe Therapeutics Inc. (TSE:ATE) Director Sells C$13,330.00 in Stock
July 14, 2022 | americanbankingnews.com
Antibe Therapeutics Inc. (TSE:ATE) Senior Officer Purchases C$12,400.00 in Stock
June 15, 2022 | nz.finance.yahoo.com
Antibe Therapeutics Announces Amendment to Warrant Terms
June 3, 2022 | finance.yahoo.com
Antibe Therapeutics Inc. (ATE.TO)
May 2, 2022 | finance.yahoo.com
Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary
February 16, 2022 | msn.com
ATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…
February 16, 2022 | finance.yahoo.com
ATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…
December 27, 2021 | finance.yahoo.com
Is There An Opportunity With Antibe Therapeutics Inc.'s (TSE:ATE) 23% Undervaluation?
November 16, 2021 | finance.yahoo.com
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results
November 1, 2021 | finance.yahoo.com
Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program
October 18, 2021 | finance.yahoo.com
ATE.TO: Pivoting to Acute Pain Relief for Otenaproxesul…
September 8, 2021 | finance.yahoo.com
Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
August 27, 2021 | finance.yahoo.com
ATE.TO: Awaiting Update on Otenaproxesul Following AME Study Pause
August 9, 2021 | finance.yahoo.com
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
August 3, 2021 | markets.businessinsider.com
Antibe Places AME Study Of Otenaproxesul On Pause Due To Pre-specified Safety Threshold Exceeded
August 3, 2021 | finance.yahoo.com
Antibe Therapeutics Provides Clinical Update for Otenaproxesul
July 27, 2021 | finance.yahoo.com
Antibe Therapeutics Provides July 2021 Corporate Update
July 23, 2021 | bloomberg.com
Antibe Therapeutics Inc
June 30, 2021 | finance.yahoo.com
We're Interested To See How Antibe Therapeutics (TSE:ATE) Uses Its Cash Hoard To Grow
June 29, 2021 | ca.finance.yahoo.com
Stocks in play: Antibe Therapeutics Inc
June 28, 2021 | finance.yahoo.com
Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights
March 29, 2021 | finance.yahoo.com
Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain
February 25, 2021 | proactiveinvestors.com
Universal Ibogaine taps biopharmaceutical veteran Dr Rami Batal as its new CEO
See More Headlines

Receive ATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATE Company Calendar

Today
8/07/2022
Next Earnings (Estimated)
8/15/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:ATE
CUSIP
N/A
CIK
N/A
Web
www.antibethera.com
Phone
+1-905-5705103
Fax
N/A
Employees
47
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$4.00
High Stock Price Forecast
C$4.00
Low Stock Price Forecast
C$4.00
Forecasted Upside/Downside
+545.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.29
Current Ratio
13.07
Quick Ratio
11.92

Sales & Book Value

Annual Sales
C$9.71 million
Price / Sales
3.33
Cash Flow
C$1.07 per share
Price / Cash Flow
0.58
Book Value
C$1.09 per share
Price / Book
0.57

Miscellaneous

Outstanding Shares
52,099,000
Free Float
N/A
Market Cap
C$32.30 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Daniel Marcel Legault J.D. (Age 64)
    L.L.B., Pres, CEO, Sec. & Director
    Comp: $481.61k
  • Dr. John Lawrence Wallace M.B.A. (Age 65)
    M.Sc., MBA, MSc, Ph.D., Founder & Vice Chair
    Comp: $481.61k
  • Mr. Alain Wilson M.B.A.
    MBA, Chief Financial Officer
  • Dr. David James Vaughan (Age 72)
    Chief Devel. Officer
    Comp: $303.34k
  • Mr. Scott Curtis C.F.A.
    M.Eng, Exec. VP
  • Dr. Joseph Stauffer D.O. (Age 56)
    M.B.A., Chief Medical Officer
    Comp: $529.17k
  • Ms. Christina Cameron B.B.A.
    VP of Investor Relations
  • Mr. Philip Stern
    VP of Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ATE Stock - Frequently Asked Questions

Should I buy or sell Antibe Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Antibe Therapeutics stock.
View analyst ratings for Antibe Therapeutics or view top-rated stocks.

What is Antibe Therapeutics' stock price forecast for 2022?

3 equities research analysts have issued twelve-month price objectives for Antibe Therapeutics' stock. Their ATE stock forecasts range from C$4.00 to C$4.00. On average, they expect Antibe Therapeutics' stock price to reach C$4.00 in the next twelve months. This suggests a possible upside of 545.2% from the stock's current price.
View analysts' price targets for Antibe Therapeutics or view top-rated stocks among Wall Street analysts.

How has Antibe Therapeutics' stock performed in 2022?

Antibe Therapeutics' stock was trading at C$0.66 at the start of the year. Since then, ATE stock has decreased by 6.1% and is now trading at C$0.62.
View the best growth stocks for 2022 here.

When is Antibe Therapeutics' next earnings date?

Antibe Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Antibe Therapeutics.

Is Antibe Therapeutics a good dividend stock?

Antibe Therapeutics(TSE:ATE) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%.

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ATE."

How do I buy shares of Antibe Therapeutics?

Shares of ATE and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Antibe Therapeutics' stock price today?

One share of ATE stock can currently be purchased for approximately C$0.62.

How much money does Antibe Therapeutics make?

Antibe Therapeutics (TSE:ATE) has a market capitalization of C$32.30 million and generates C$9.71 million in revenue each year.

How many employees does Antibe Therapeutics have?

Antibe Therapeutics employs 47 workers across the globe.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The official website for Antibe Therapeutics is www.antibethera.com. The company can be reached via phone at +1-905-5705103.

This page (TSE:ATE) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.